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Open access under CC BSeveral L-fucoglycolipids are associated with diseases such as cancer, cystic ﬁbrosis and rheumatoid
arthritis. Activation of iNKT cells is known to lead to the production of cytokines that can help alleviate
or exacerbate these conditions. a-Galactosyl ceramide (a-GalCer) is a known agonist of iNKT cells and
it is believed that its fucosyl counterpart might have similar immunogenic properties. We herein report
the synthesis of a-L-fucosyl ceramide derivatives and describe their biological evaluation. The key chal-
lenge in the synthesis of the target molecules involved the stereoselective synthesis of the a-glycosidic
linkage. Of the methods examined, the per-TMS-protected glycosyl iodide donor was completely a-
selective, and could be scaled up to provide gram quantities of the azide precursor 11, from which a
range of N-acylated a-L-fucosyl ceramides were readily obtained and evaluated for ex vivo expansion
of human iNKT cells.
 2010 Elsevier Ltd. Open access under CC BY license.Both D- and L-fucose (6-deoxy galactose) are widely found in
nature.1 Of interest, L-fucose is predominantly found in the a-
conﬁguration in the lipopolysaccharides (LPS) of Gram-negative
bacteria and animal glycosphingolipids.1,2 With the exception
of the monohexylceramide, a-L-fucosylceramide 1, initially iso-
lated from metastatic human adenocarcinoma,3 most fucosphin-
golipids are usually ceramide oligosaccharides.2,4 Many of these
fucolipids are antigenic5–7 and play a role in tumour cell biol-
ogy.8–10 Conversely, the synthetic glycolipid, a-galactosyl cera-
mide (a-GalCer)11 (2), is a strong agonist of iNKT cells when
bound to CD1d, triggering the release of diverse cytokines,
including both Th1 and Th2 cytokines.12–14 It is believed that
the release of Th1 cytokines may contribute to antitumour and
antimicrobial functions while that of Th2 cytokines may help
alleviate autoimmune diseases15–17 such as multiple sclerosis18
and arthritis.19Y license.O
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a-GalCer and its derivatives have proved to be and remain
invaluable tools in understanding the functioning of CD1d and
iNKT cells in a wide range of immune responses. Crystal structures
of the bound a-GalCer–CD1d complex20–22 showed that the hydro-
xyl group at C-6 in the sugar head is not crucial for binding to the
T-cell receptor (TCR) as opposed to C-2, C-3 and C-4. Hence, the a-
D-fucosylceramide 323 was shown to be a potent inducer of IFN-c
3224 N. Veerapen et al. / Bioorg. Med. Chem. Lett. 20 (2010) 3223–3226in mice in vivo, while a slightly different derivative, synthesised by
Motoki et al.24 showed strong lymphocytic proliferation stimula-
tory effects in vitro in mice.
While there are a few examples describing the synthesis of a-L-
fucosylceramide 4b25 and other derivatives in the literature,26,27
their biological activities are yet to be fully explored. As part of var-
ious ongoing studies, and because of the aforementioned reasons,
we have synthesised compounds 4a–4d for biological evaluation
and comparative studies.
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+Fan et al. reported the synthesis of compound 4d, while
Okamoto et al.27 reported that of compound 4e. Both groups ob-
tained their target compounds as an a, b mixture (3:1 ratio) from
different glycosyl donors and acceptors (Scheme 1). On the other
hand, in the original reported synthesis of the fucosylceramide 1,
only the a-anomer was isolated when another ceramide acceptor
was used under different reaction conditions.
We recently reported the synthesis28 of a-GalCer and other
derivatives where we used N-iodosuccinimide (NIS) and triﬂic acid
(TfOH) as a promoter, and benzoate protecting groups on the
sphingosine base. Along with the nature of the protecting groups
on both the glycosyl acceptor and donor, the choice of promoter,
as well as temperature and reaction times can affect the stereose-
lectivity of the glycosylation reaction. In this study, we proposed to
investigate whether our glycosyl acceptor 7 and reaction condi-
tions could offer a better a-selectivity in the case of L-fucose.SPh
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Scheme 1. (a) Me2S, 2-Cl-pyridine, Tf2O, CH2Cl2; (b) dimethyl(methylthio)sulfo-
nium triﬂate (DMTST), CH2Cl2, 0 C-rt.The phytosphingosine acceptor 729 was synthesised from
(2S,3S,4R)-2-azido-1,3,4-octadecanetriol30 as described before. Gi-
ven the previous success of a thiogalactoside in a similar glycosyl-
ation reaction with compound 728 we chose to use the thiofucosyl
donor 6, rather than compound 5. The thioglycoside 6was thus ob-
tained from commercially available L-fucose after standard proce-
dures, as previously reported.31
With both the acceptor and donor in hand, we then proceeded
to the critical glycosylation reaction. Interestingly, NIS/TfOH acti-
vation of 1 g of the thioglycoside 6 (Scheme 2) in anhydrous CH2Cl2
at 78 C afforded the glycosylated compound 8, almost exclu-
sively as the a-anomer (a:b ratio = 9:1), in 68% yield after 2 h.
Our results show a deﬁnite improvement in selectivity from the
previously reported syntheses. Because the formation of the a-
anomer is favoured by the anomeric effect, we rationalise that
the latter is a governing factor under our reaction conditions. Both
the lower temperature and the different reactivity of the acceptor 7
could potentially inﬂuence the stereoselectivity of the glycosyla-
tion reaction. These factors will have to be more thoroughly inves-
tigated in a later study. Subsequent Zemplen’s deprotection of the
benzoate protecting groups produced the azide intermediate in
quantitative yields. Tandem hydrogenation of the azido group
and hydrogenolysis of the benzyl ethers in methanol then pro-
duced the amine 9 as a white solid, which exhibited spectroscopic
data consistent with the literature.25
In an attempt to improve the stereoselectivity and circumvent
the sometimes problematic removal of the benzyl ethers by
hydrogenolysis, we embarked on a different glycosylation route.
Recently, the use of glycosyl iodide donors has been revived by
Gervay-Hague’s group.32,33 They have demonstrated that glycosyl-
ation reactions employing glycosyl iodides and promoted by tetra-
butyl ammonium iodide (TBAI) are generally quite stereoselective
and fast. It has been hypothesized that TBAI catalyses the isomer-
ization of the a-glycosyl iodide to the b-anomer,34 thereby leading
to the formation of an a-glycoside. They have successfully adapted
this strategy to the synthesis of a-GalCer35 and other a-fucosylgly-
cosides.36 Furthermore, the replacement of the benzyl ethers with
trimethylsilylethers (TMS) made Gervay-Hague’s synthetic strat-
egy even more attractive. TMS protected sugars are easy to gener-
ate and their deprotection requires very mild acidic conditions,
compatible with the glycosidic linkage.OBn
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Scheme 2. (a) NIS/TfOH, CH2Cl2, 78 C to 20 C, 68%; (b) NaOMe/MeOH, 92%; (c)
H2, Pd, 76%.
N. Veerapen et al. / Bioorg. Med. Chem. Lett. 20 (2010) 3223–3226 3225The per-O-trimethylsilyl-a-L-fucosylpyranosyl iodide 10 was
generated by the reaction of the per-O-tetramethylsilyl-a-L-fucose
with one equivalent of iodotrimethylsilane35 and then added to the
phytosphingosine acceptor 7 which was premixed with diisopro-
pylethylamine (DIPEA) and TBAI (Scheme 3). After 2 days at room
temperature, the solvent was evaporated and the TMS protecting
groups were removed by treatment with an acidic resin in MeOH.
Compound 11 was obtained as the a-anomer exclusively in an
overall yield of 62%. The formation of the desired a-linkage was
conﬁrmed by the H-1 and C-1 signals in 1H and 13C NMR. Methan-
olysis, followed by hydrogenation of the azide then afforded com-
pound 9.
Finally, N-acylation with the fully saturated fatty acids, tetraco-
sanoic acid (C24:0) and hexacosanoic acid (C26:0), was achieved
via reaction of the corresponding acid chloride with the free amine
9 in a 1:1 mixture of THF and saturated sodium acetate solution
(Scheme 3). Target compounds 4c and 4d were obtained as white
solids after concentration of the organic phase and puriﬁcation of
the residue by ﬂash chromatography. The spectroscopic data of
the ﬁnal compounds were consistent with the literature.25 While
compound 4a was obtained by heating amine 9 with the
N-hydroxysuccinimide activated ester of C20:2 fatty acid in a mix-
ture of pyridine: water (9:1) at 50 C overnight, compound 4b was
obtained via dicyclohexylcarbodiimide (DCC) activated coupling
using procedures described previously.37,38
To assess the biological activity of the a-L-fucosylceramides and
compare these to a-GalCer (KRN7000, 2), we assessed the ability of
each compound to induce the expansion of iNKT cells in samples of
human peripheral blood mononuclear cells (PBMC) during an
eight-day in vitro culture.39 The results showed that both the per-
centages and absolute numbers of iNKT cells in cultures were in-
creased by stimulation with a-L-fucosylceramides with C26:0I
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Scheme 3. (a) TBAI, DIPEA, CH2Cl2, rt; (b) Dowex 50WX8-200, MeOH, rt, 62% over
two steps; (c) NaOMe/MeOH, quantitative; (d) H2, Pd, MeOH, 80%; (e) C25H51COCl or
C23H47COC1, THF, NaOAc, 78–80%.(4d) > C18:0 (OH) (4b) > C24:0 (4c). The a-L-fucosylceramide con-
taining a C26:0 fatty acid (4d) was the most active of the fucosyl
series, and stimulated iNKT cell expansions in some donors that
approached those seen with the prototype iNKT cell agonist
KRN7000 (2). In contrast, the a-L-fucosylceramide containing the
C20:2 fatty acid (4a) was found to lack detectable iNKT cell stimu-
lating activity in any of the donors tested (Fig. 1B). Representative
proﬁles obtained by ﬂow cytometry of cultures from one normal
blood donor are shown in Figure 1A. This analysis was carried
out with PBMC from four separate donors (Fig. 1B). Although, dif-
ferences were observed for the levels of iNKT cell expansion be-
tween different donors, all donors responded signiﬁcantly to two
of the a-L-fucosylceramide analogues (4b and 4d).
In summary, in the current study we have developed an
efﬁcient method for the synthesis of a series of biologically active
a-L-fucosylceramides.40 The second method, employing the per-
O-trimethylsilyl-a-L-fucosylpyranosyl iodide 10, proved to be
superior with a better a-selectivity and reasonably good yield in
the glycosylation reaction. Given the marked difference in the ste-
reochemistry of the a-fucosyl head group of these glycolipids com-
pared to a-galactosyl group of strong iNKT cell activators like
KRN7000, it is surprising that the compounds in the current series
show such substantial activity. This would seem to further rein-
force the notion that the TCR of iNKT cells, in spite of its relative
limited variability, is nevertheless able to interact efﬁciently with
a broad range of structurally diverse ligands. It is noteworthy thatFigure 1. Ex vivo expansion of human iNKT cells by a-L-fucosylceramides. PBMC from
four different donors were stimulated with the indicated glycolipids at a concen-
tration of 250 nM in the presence of low levels of exogenous IL-2 and IL-7. At day 8,
cultures were harvested and analysed by ﬂow cytometry using monoclonal
antibodies speciﬁc for CD3 and for the invariant TCRa chain expressed by iNKT
cells (6B11). (A) Dot plots showing relative levels of CD3+ 6B11+ iNKT cells are
shown for one representative donor. Numbers in upper right quadrant indicate
percentages of total lymphocytes that are iNKT cells. (B) Absolute numbers of iNKT
cells in the cultures were determined by ﬂow cytometry using ﬂuorescent counting
beads, and the values of iNKT cell fold expansion were determined by dividing by
the input number of iNKT cells.
3226 N. Veerapen et al. / Bioorg. Med. Chem. Lett. 20 (2010) 3223–3226the C20:2 N-acyl variant of a-fucosylceramide (4a) showed no
detectable iNKT cell stimulating activity, given that the a-galacto-
syl version of this compound is an extremely potent iNKT cell ago-
nist.41 This suggests that modiﬁcation of the carbohydrate moiety
can signiﬁcantly alter the inﬂuence of the lipid moiety of the ligand
on CD1d presentation and iNKT cell responses. Although the mech-
anism for this remains unclear, it is an important consideration for
synthetic strategies that seek to combine biologically active alter-
ations of the carbohydrate and lipid moieties of iNKT cell ligands.
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